{
  "docId": "019de073-bcea-715e-8f3b-2af68c1e6615",
  "docSlug": "cfcb19cc2b89b85461a28b4631a8b033",
  "documentTitle": "Hepion Pharmaceuticals | Results Presentation Deck | 34 slides",
  "authorId": "hepion-pharmaceuticals",
  "authorName": "Hepion Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 24,
  "pageCount": 34,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide defines the success criteria for the trial based on liver histology improvements.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-bcea-715e-8f3b-2af68c1e6615/24",
  "deckHref": "/decks/019de073-bcea-715e-8f3b-2af68c1e6615",
  "deckJsonHref": "/decks/019de073-bcea-715e-8f3b-2af68c1e6615.json",
  "deckAnchorHref": "/decks/019de073-bcea-715e-8f3b-2af68c1e6615#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.5,
        "x": 0.13,
        "y": 0.55
      },
      "kind": "list",
      "text": "At least 1 stage regardless of effect on NASH\nAt least 2 stages regardless of effect on NASH\nAt least 2 stages AND no worsening of NASH.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92673391-d1e5-40a2-8735-53b5b7c5ef5f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.1,
        "y": 0.45
      },
      "kind": "paragraph",
      "text": "Secondary Efficacy Endpoints: Superiority of rencofilstat compared to placebo on histology at month 12 relative to screening by assessing the proportion of subjects with improvement in fibrosis by:",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "17ad9098-85d1-4859-9276-569af3484cce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.1,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Primary Efficacy Endpoint: Superiority of rencofilstat compared to placebo on liver histology at month 12 relative to the screening biopsy, by assessing the proportion of subjects with improvement in fibrosis by at least 1 stage (NASH CRN system) OR NASH resolution without worsening of fibrosis",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aed3d935-a696-4cbb-ae1f-86fe2b427d7d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.06,
        "y": 0.06
      },
      "kind": "title",
      "text": "Phase 2b ASCEND-NASH",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94f5ec4f-c29e-4e47-828b-2ec8b172d7ae",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}